These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25764966)

  • 1. Evaluating response to disease-modifying therapy in relapsing multiple sclerosis.
    Freedman MS; Abdoli M
    Expert Rev Neurother; 2015 Apr; 15(4):407-23. PubMed ID: 25764966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging oral drugs for relapsing-remitting multiple sclerosis.
    Gasperini C; Ruggieri S
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):697-712. PubMed ID: 22148963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple sclerosis patients and immunomodulation therapies: the potential role of new MRI techniques to assess responders versus non-responders.
    Tedeschi G; Gallo A
    Neurol Sci; 2005 Dec; 26 Suppl 4():S209-12. PubMed ID: 16388360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of the management of relapsing-remitting multiple sclerosis and practical recommendations.
    Gallo P; Van Wijmeersch B;
    Eur J Neurol; 2015 Oct; 22 Suppl 2():14-21. PubMed ID: 26374509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design.
    Cascione M; Wynn D; Barbato LM; Pestreich L; Schofield L; McCague K
    J Med Econ; 2013 Jul; 16(7):859-65. PubMed ID: 23647445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
    Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
    JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis.
    Fox EJ; Rhoades RW
    Curr Opin Neurol; 2012 Feb; 25 Suppl():S11-9. PubMed ID: 22398660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of diagnosis and early treatment on the course of multiple sclerosis.
    Noyes K; Weinstock-Guttman B
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s321-31. PubMed ID: 24494633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Glatiramer acetate in interferon beta non respondent relapsing-remitting multiple sclerosis].
    Oreja-Guevara C; Bermejo PE; Miralles A; Gabaldón L; Aguilar MJ; Díez-Tejedor E
    Neurologia; 2009 Sep; 24(7):435-8. PubMed ID: 19921551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early treatment in multiple sclerosis.
    Elovaara I
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S24-8. PubMed ID: 22206762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Update on current care guidelines: diagnostics, treatment and rehabilitation of multiple sclerosis].
    Elovaara I; Atula S; Erälinna JP; Färkkilä M; Pirttilä T; Remes A; Ruutiainen J; Varis T; ;
    Duodecim; 2010; 126(2):199-200. PubMed ID: 20405605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary progressive multiple sclerosis: current knowledge and future challenges.
    Rovaris M; Confavreux C; Furlan R; Kappos L; Comi G; Filippi M
    Lancet Neurol; 2006 Apr; 5(4):343-54. PubMed ID: 16545751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP; Martín-Medina P; Berenguer-Ruiz L; Pérez-Carmona N; Sanchez-Perez R; Polache-Vengud J; Feliu-Rey E
    Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can we discontinue disease-modifying treatments in multiple sclerosis patients? Comments.
    Gouider R
    Rev Neurol (Paris); 2017; 173(1-2):44-46. PubMed ID: 27919465
    [No Abstract]   [Full Text] [Related]  

  • 18. Current management of relapsing-remitting multiple sclerosis.
    Sedal L; Wilson IB; McDonald EA
    Intern Med J; 2014 Oct; 44(10):950-7. PubMed ID: 25302718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
    Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the treatment of relapsing-remitting multiple sclerosis.
    Tanasescu R; Ionete C; Chou IJ; Constantinescu CS
    Biomed J; 2014; 37(2):41-9. PubMed ID: 24732658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.